Health4 weeks ago
GSK’s Blood Cancer Drug Review Extended Despite FDA Advisory Vote
GlaxoSmithKline (GSK) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended the review period for its blood cancer therapy, Blenrep. This development...
